Bayer and NextRNA Therapeutics Enter Strategic Collaboration to Develop Small Molecules Targeting Long Non-Coding RNAs (lncRNAs) in Oncology
Bayer and NextRNA Therapeutics Enter Strategic Collaboration to Develop Small Molecules Targeting Long Non-Coding RNAs (lncRNAs) in Oncology
08/28/24, 11:04 AM
Location
Industry
biotechnology
Type
partnership
Bayer and NextRNA Therapeutics have entered into a collaboration and license agreement to develop small molecule therapeutics targeting lncRNAs in oncology. This partnership aims to advance novel small molecule therapeutics against a new class of targets in oncology.
Company Info
Location
40 guest st.
boston, massachusetts, united states
Additional Info
NextRNA Therapeutics, Inc. is a Boston-based biotechnology company leading the next revolution of RNA-directed therapeutics. Our focus is on identifying and drugging long non-coding RNAs (lncRNAs) with small molecules in oncology and neuroscience.
Our proprietary computational engine, combined with deep lncRNA biology expertise and strong drug discovery capabilities, positions us well to unlock the therapeutic value of lncRNAs, a vast and promising target space.
NextRNA has assembled an experienced team of industry leaders, biology and chemistry experts, and drug developers, all driven by a common passion for working together and having an impact on science and patients.
Related People

Unlock Verified Contacts + AI Outreach
Instantly access verified contact emails — and let Fundz AI draft a hyper-personalized message based on their role, company, and your company's offering.
Jh
Jh • Executive
Email hidden • Upgrade to unlock
Trusted by teams at Google, Oracle, HubSpot & more